Astellas Pharma Inc (JP:4503)
:4503
Top Page
Astellas Pharma
(4503)
Select Model
Select Model
Rating:75Outperform
Price Target:
¥2,724.00
▲(38.66% Upside)
Action:ReiteratedDate:02/06/26
The score is driven primarily by improved TTM profitability and solid free-cash-flow generation, supported by reasonable valuation and a strong dividend yield. Technicals are constructive (price above major moving averages and positive MACD) but tempered by overbought conditions (high RSI), which adds near-term risk.
Positive Factors
High TTM profitability
TTM margins around 76% gross and ~20% EBIT indicate durable pricing power and operational efficiency for a large pharma. Sustained high margins support internal R&D funding, manufacturing scale, and dividend capacity, strengthening long-term reinvestment ability and resilience.
Negative Factors
Rising leverage
Leverage increased materially versus prior years, reducing financial flexibility and raising interest and refinancing risk. Higher debt levels can constrain M&A appetite, increase cost of capital, and pressure investment or dividend plans if cash flow weakens or macro conditions deteriorate.
Read all positive and negative factors
Positive Factors
Negative Factors
High TTM profitability
TTM margins around 76% gross and ~20% EBIT indicate durable pricing power and operational efficiency for a large pharma. Sustained high margins support internal R&D funding, manufacturing scale, and dividend capacity, strengthening long-term reinvestment ability and resilience.
Read all positive factors
Astellas Pharma (4503) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥4.25T
Dividend Yield3.61%
Average Volume (3M)8.39M
Price to Earnings (P/E)9.3
Beta (1Y)0.64
Revenue Growth13.24%
EPS Growth127.88%
CountryJP
Employees14,754
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)56.04
Shares Outstanding1,809,663,100
10 Day Avg. Volume8,158,160
30 Day Avg. Volume8,386,496
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)1.71
Price to Sales (P/S)1.35
P/FCF Ratio15.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥2,295.00Price Target Upside16.82% Upside
Rating ConsensusHold
Number of Analyst Covering10
EPS Forecast (FY)140.3
Revenue Forecast (FY)¥2.11T
Astellas Pharma Business Overview & Revenue Model
Company Description
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relaps...
How the Company Makes Money
Astellas Pharma generates revenue primarily through the sale of prescription medications and biologics. The company has a diverse portfolio of products that contribute to its earnings, with key revenue streams coming from high-demand therapies in ...
Astellas Pharma Earnings Call Summary
Earnings Call Date:Apr 25, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:Apr 23, 2026
Earnings Call Sentiment Positive
Astellas Pharma demonstrated strong financial performance with record-breaking revenue and significant growth in Strategic Brands. Successful cost optimization and a positive outlook for FY 2025, including increased dividends and progress in primary focus programs, highlight a positive trajectory. Despite challenges such as the impact of U.S. Medicare Part D redesign and temporary demand issues with IZERVAY, the overall sentiment remains optimistic.Positive Updates
Record-Breaking Revenue and Growth
In FY 2024, Astellas Pharma reported record high revenue of ¥1.912 trillion, a 19.2% increase year-on-year, and core operating profit of ¥392.4 billion, up by 41.7% year-on-year.
Negative Updates
Impact of U.S. Medicare Part D Redesign
The redesign led to a gross-to-net impact on XTANDI sales in the U.S., although volume growth offset some of this impact.
Read all updates
Q4-2024 Updates
Positive
Negative
Record-Breaking Revenue and Growth
In FY 2024, Astellas Pharma reported record high revenue of ¥1.912 trillion, a 19.2% increase year-on-year, and core operating profit of ¥392.4 billion, up by 41.7% year-on-year.
Read all positive updates
Company Guidance
During the FY 2024 financial results announcement by Astellas Pharma Inc., several key financial metrics were highlighted, indicating a record year for the company. Revenue reached ¥1.912 trillion, marking a 19.2% increase year-on-year, while core operating profit rose by 41.7% to ¥392.4 billion. The company achieved significant growth in its Strategic Brands, with sales exceeding ¥340 billion, reflecting a growth of ¥180 billion or 110% year-on-year. The core operating profit margin improved by 3.3 percentage points to 20.5%. Astellas also reported substantial cost optimization, achieving a target of ¥40 billion, which improved the SG&A ratio by 3.1 percentage points. The Forex impact positively contributed ¥68.1 billion to revenue and ¥15.1 billion to core operating profit. Looking forward, Astellas forecasts further growth in FY 2025, with expected revenue of ¥1.930 trillion and a core operating profit increase to ¥410 billion, driven by continued expansion in Strategic Brands and ongoing cost optimization efforts.Astellas Pharma Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
67
Positive
Cash Flow
72
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.06T | 1.91T | 1.60T | 1.52T | 1.30T | 1.25T |
| Gross Profit | 1.60T | 1.56T | 1.31T | 1.23T | 1.04T | 1.00T |
| EBITDA | 624.37B | 462.67B | 282.45B | 337.39B | 297.83B | 323.58B |
| Net Income | 322.85B | 50.75B | 17.05B | 98.71B | 124.09B | 120.59B |
Balance Sheet | ||||||
| Total Assets | 3.60T | 3.34T | 3.57T | 2.46T | 2.33T | 2.27T |
| Cash, Cash Equivalents and Short-Term Investments | 254.30B | 188.37B | 335.69B | 376.84B | 315.99B | 326.13B |
| Total Debt | 725.27B | 937.09B | 1.01T | 200.01B | 212.74B | 278.26B |
| Total Liabilities | 1.84T | 1.83T | 1.97T | 948.56B | 872.09B | 887.51B |
| Stockholders Equity | 1.76T | 1.51T | 1.60T | 1.51T | 1.46T | 1.39T |
Cash Flow | ||||||
| Free Cash Flow | 413.15B | 164.61B | 143.27B | 295.88B | 227.42B | 276.50B |
| Operating Cash Flow | 463.97B | 201.61B | 181.32B | 332.32B | 258.16B | 307.88B |
| Investing Cash Flow | -55.07B | -96.52B | -854.65B | -89.06B | -63.13B | -82.93B |
| Financing Cash Flow | -337.44B | -261.37B | 614.06B | -195.62B | -216.30B | -229.48B |
Astellas Pharma Technical Analysis
Neutral
1964.50
Price Trends
2369.98
Negative
2180.26
Positive
1852.11
Positive
Market Momentum
-3.27
Positive
46.60
Neutral
30.88
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4503, the sentiment is Neutral. The current price of 1964.5 is below the 20-day moving average (MA) of 2423.87, below the 50-day MA of 2369.98, and above the 200-day MA of 1852.11, indicating a neutral trend. The MACD of -3.27 indicates Positive momentum. The RSI at 46.60 is Neutral, neither overbought nor oversold. The STOCH value of 30.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4503.
Astellas Pharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
84 Outperform | ¥13.07T | 31.26 | 22.23% | 1.17% | 6.25% | 2.62% | |
84 Outperform | ¥2.92T | 8.09 | 12.22% | 2.22% | 4.48% | 11.08% | |
75 Outperform | ¥4.25T | 9.34 | 7.97% | 3.61% | 13.24% | 127.88% | |
72 Outperform | ¥1.23T | 19.73 | 4.27% | 2.33% | -3.36% | -55.41% | |
68 Neutral | ¥1.32T | 19.13 | 5.75% | 3.51% | 6.79% | 22.14% | |
63 Neutral | ¥5.52T | 17.88 | 18.56% | 2.07% | 12.56% | 14.58% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:4503
Astellas Pharma
2,485.50
1,057.15
74.01%
JP:4519
Chugai Pharmaceutical Co
8,224.00
1,406.84
20.64%
JP:4568
Daiichi Sankyo Company
3,010.00
-632.24
-17.36%
JP:4523
Eisai Co
4,809.00
633.63
15.18%
JP:4151
Kyowa Kirin Co
2,395.00
270.96
12.76%
JP:4507
Shionogi & Co
3,319.00
1,051.02
46.34%
Astellas Pharma Corporate Events
Astellas Lifts FY2025 Outlook on Robust XTANDI and Mirabegron Demand
Feb 4, 2026
Astellas raised its FY2025 core and full-basis revenue and profit forecasts on the back of stronger-than-expected global demand for prostate cancer therapy XTANDI and overactive bladder franchise Mirabegron, amplified by favorable foreign exchange...
Astellas and Pfizer Unveil Breakthrough in Bladder Cancer Treatment
Dec 17, 2025
Astellas Pharma and Pfizer announced pivotal Phase 3 trial results for PADCEV combined with Keytruda, marking a significant advancement in muscle-invasive bladder cancer treatment. The trial highlights considerable survival improvement without pla...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.